How Fosamax Triggers Osteonecrosis of the Jaw: Pathophysiology and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Communication

The legacy of general health and science information has long emphasized the importance of patient education and preventive care within community-based medical settings. In this tradition, family practice and urgent care clinics serve as accessible hubs for disseminating knowledge about medication safety and potential adverse effects. As patients transition from routine health maintenance to more specialized therapeutic interventions, the need for targeted risk communication becomes increasingly apparent. This is particularly relevant when considering the shift from broad health guidance to specific concerns about pharmaceutical exposure. In the context of mass production environments, where workers may encounter various chemical agents, the focus narrows to occupational exposure scenarios. The same principles of informed consent and risk awareness that guide general patient care now apply to workplace settings, where employees might be exposed to substances with known health implications. This transition from general health literacy to occupational hazard recognition requires a careful pivot, acknowledging that the mechanisms of harm in industrial contexts may differ from those in clinical populations. The bridge between these domains lies in the shared commitment to preventing harm through education, whether the exposure occurs in a doctor's office or on a factory floor.

Bridging to Fosamax and Osteonecrosis of the Jaw

While occupational exposures present unique challenges, the same principles of risk communication apply to pharmaceutical agents used in clinical practice. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover and increases bone mineral density. However, this suppression of normal bone remodeling has been linked to a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The pathophysiology of how Fosamax triggers ONJ involves several interconnected mechanisms, primarily related to its potent inhibition of osteoclast activity. The jawbone has unique characteristics that make it particularly susceptible to bisphosphonate-related complications. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including postmenopausal osteoporosis and bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Research using animal models has examined the effects of bisphosphonate treatment on jawbone properties. In a study using estrogen-deficient rats, treatments with bisphosphonate (alendronate, ALN), parathyroid hormone (PTH), and their combination were evaluated for their effect on the jawbone. The study involved ovariectomized rats assigned to groups receiving saline injection, PTH following saline injection, bisphosphonate (ALN), or a combination (ALN/PTH). A hemimandible was randomly dissected from each rat for multiscale characterization including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the mechanical and structural properties of the jawbone, potentially predisposing it to necrosis.

Mechanistic Pathway and Risk Factors

The mechanistic pathway linking Fosamax to ONJ begins with the drug's accumulation in bone, particularly at sites of high bone turnover such as the jaw. Bisphosphonates like alendronate bind strongly to hydroxyapatite crystals and are released during bone resorption, where they are taken up by osteoclasts and inhibit their function. This suppression of osteoclast activity reduces the normal process of bone remodeling, which is essential for repairing microdamage and maintaining bone health. In the jaw, where teeth are subjected to constant mechanical stress and where dental procedures or infections can create localized areas of high bone turnover, the lack of remodeling can lead to the accumulation of microdamage and eventual necrosis. Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline and Causation Considerations

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding causation considerations for affected patients, the relationship between Fosamax use and ONJ is supported by clinical reports and mechanistic plausibility. The drug's labeling explicitly states that ONJ has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the condition can also occur spontaneously, and the presence of other risk factors complicates the determination of causation in individual cases. The adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information, which includes a specific section on osteonecrosis of the jaw under warnings and precautions. This section describes the condition, associated risk factors, and the potential for increased risk with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast activity, suppressing bone remodeling. This leads to accumulation of microdamage in the jawbone, especially after dental procedures or infections, resulting in non-healing exposed bone. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate use increases risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How long after starting Fosamax can ONJ develop?

Onset of symptoms can vary from one day to several months after starting the drug. Most patients improve after stopping, but symptoms may recur upon rechallenge. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.